• Two additional Complete Responses (CRs) observed in Imugene's Phase 1b trial of azer-cel
• Four out of seven patients have now achieved a complete response following treatment
• Patients had previously failed 4-5 lines of therapy, including autologous CAR-T

Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, has announced more positive results from its Phase 1b clinical trial evaluating azer-cel (azercabtagene zapreleucel) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Following the previously reported results on 2 September 2024, two additional patients in the previously reported Cohort B - treatment with azer-cel, lymphodepletion (chemotherapy), and interleukin 2 (IL-2) - have now achieved a Complete Response (CR, being the disappearance of all signs of cancer in response to the treatment), bringing the total to four out of seven evaluable patients in this cohort. These patients had previously failed 4-5 lines of therapy, including autologous CAR T therapy, reinforcing the potential of azer-cel in this high-unmet-need population. The company remains focused on continuing enrolment in Cohort B and evaluating the long-term durability of responses. Azer-cel is being developed as a potential off-the-shelf CAR T-cell therapy, addressing key limitations of autologous CAR T approaches, including treatment accessibility and manufacturing constraints.

The company remains focused on continuing enrolment in Cohort B and evaluating the long-term durability of responses. Azer-cel is being developed as a potential off-the-shelf CAR T-cell therapy, addressing key limitations of autologous CAR T approaches, including treatment accessibility and manufacturing constraints.